Ana Giménez‐Capitán

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rafael Rosell, Miguel Angel Molina, Carlota Costa et al. · Clinical Cancer Research · 2011 · 300 citations · Full text

Medicine, Molecular Biology, Oncology +17

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Niki Karachaliou, María González‐Cao, Guillermo Crespo et al. · Therapeutic Advances in Medical Oncology · 2018 · 274 citations · Full text

Medicine, Immunology, Oncology +17

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj et al. · Clinical Cancer Research · 2014 · 228 citations · Full text

Medicine, Oncology, Pharmacology +15

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer

R. Jonas A. Nilsson, Niki Karachaliou, Jordi Berenguer et al. · Oncotarget · 2015 · 200 citations · Full text

Medicine, Hematology, Oncology +14

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Kirstine Jacobsen, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila et al. · Nature Communications · 2017 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17